DFDA

Cemiplimab

Treatment for Non Melanoma Skin Cancer Squamous Cell Carcinoma

Typical Dosage: 350 mg IV every 3 weeks

Effectiveness
88%
Safety Score
40%
Clinical Trials
7
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
350 mg IV every 3 weeks
Time to Effect
2-4 months
Treatment Duration
Months to years
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$153,000
Monitoring:$3,000
Side Effect Mgmt:$7,000
Total Annual:$163,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$200,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$362,222
Cost per Remission
$905,556
Comparison vs Systemic Chemotherapy
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Cemiplimab Outcomes

for Non Melanoma Skin Cancer Squamous Cell Carcinoma

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+45%
Remission Rate
+18%
Common Side Effects
Fatigue
+40%
Musculoskeletal pain
+30%
Rash
+25%
Diarrhea
+20%
Immune-related adverse events
+10%

Sources:

conexiant.com
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
4 active trials recruiting for Cemiplimab in Non Melanoma Skin Cancer Squamous Cell Carcinoma

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

NCT05878288ACTIVE NOT RECRUITINGPHASE2
View Study
11 participants
INTERVENTIONAL
Melbourne, Australia
Started: May 26, 2023

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410RECRUITINGPHASE3
View Study
369 participants
INTERVENTIONAL
Phoenix, United States +40 more
Started: Jan 2, 2025

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

NCT05574101ACTIVE NOT RECRUITINGPHASE2
View Study
34 participants
INTERVENTIONAL
Aurora, United States +12 more
Started: Oct 6, 2022

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029RECRUITINGPHASE1
View Study
168 participants
INTERVENTIONAL
Los Angeles, United States +15 more
Started: Oct 13, 2023
Completed Clinical Trials
1 completed trial for Cemiplimab in Non Melanoma Skin Cancer Squamous Cell Carcinoma

Comparative Efficacy of Cemiplimab to Historical Standard of Care in France

NCT05302297COMPLETED
View Study
305 participants
OBSERVATIONAL
France, France
Started: Jan 17, 2022